RecruitingEarly Phase 1NCT07601269
Replacement of the Native Mitral Valve Using the ReValve System
A Clinical Study Evaluating the Replacement of the Native Mitral Valve Using the ReValve System
Sponsor
ReValve Solutions Inc.
Enrollment
25 participants
Start Date
Apr 26, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This study is to collect preliminary chronic information on performance and safety of the ReValve System.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Symptomatic functional and/or degenerative MR (≥2+) due to ischemic and non-ischemic cardiomyopathy etiology determined by assessment of a qualifying transthoracic echocardiogram (TTE) obtained within 60 days and transesophageal echocardiogram (TEE) obtained within 90 days prior to subject registration, with MR severity based principally on the TTE study.
- New York Heart Association (NYHA) Functional Class II, III or ambulatory IV.
- Left Ventricular Ejection Fraction (LVEF) is ≥30% (within 90 days prior to subject registration, assessed by the site using any one of the following methods: echocardiography, contrast left ventriculography, gated blood pool scan or cardiac CT.
- Age greater than 18 years.
- Left Ventricular End Systolic Dimension (LVESD) is ≤ 65 mm assessed by site based on a transthoracic echocardiographic (TTE) obtained within 90 days prior to subject consent.
Exclusion Criteria8
- Untreated clinically significant coronary artery disease requiring revascularization.
- Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months.
- Status 1 heart transplant or prior orthotopic heart transplantation.
- Cerebrovascular accident within 30 days prior to subject's consent.
- Pregnant or planning pregnancy within next 12 months.
- Currently participating in an investigational drug or another device study.
- Evidence of LV or LA thrombus, vegetation or mass
- Known hypersensitivity or contraindication to procedural, post procedural medication (e.g., contrast solution, anticoagulation therapy) or hypersensitivity to nickel or titanium.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEReValve System
Mitral Valve Replacement Device
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07601269